Introduction: Quality-of-life (QOL) assessments in frequently bleeding patients with congenital hemophilia with inhibitors and their families are confounded by preexisting arthropathy and family circumstances. Periodic QOL assessments typically made on nonbleed days may not provide complete reflections of the burden on patients/families. Aim: To evaluate the impact of bleeding episodes on patients/caregivers/families and the association between monthly QOL scores and patients' average diary experiences. Methods: Frequently bleeding inhibitor patients (Նfour bleeds in 3 months), or their caregivers, provided daily assessment of EuroQol five-dimensional questionnaire and EuroQol five-dimensional questionnaire visual analogue scale, pain (11-point Likert scale), and family anxiety/stress/activity change over 3 to 6 months. QOL scores were stratified by bleed/nonbleed days. Results: Patient QOL assessments were recorded by 37 of the 39 enrolled patients/caregivers (3771 of 3777 eligible dairy days, 472 bleed/ 3299 nonbleed days). Median (range) diary duration was 91 (66 -180) days, with 8.2% (0%-72.2%) bleed days. Mean health scores were significantly worse on bleed days than on nonbleed days (P Ͻ 0.0001 for all): EuroQol five-dimensional questionnaire index, 0.66 versus 0.82; visual analogue scale health, 69.7 versus 77.4; and pain score, 4.1 versus 1.8. Bleed days also had higher (P Ͻ 0.001) proportions of days with abnormalities in family anxiety/stress (42% vs. 30%) and family activity changes (34% vs. 21%). Conclusions: Assessing the impact of hemophilia with inhibitors on patient/family QOL typically includes periodic (likely nonbleed day) evaluations reflecting baseline abnormalities. Daily assessment, however, indicated that frequent acute bleeds impair QOL beyond patient's nonbleed day baseline. New approaches are required to assess the cumulative impact of frequent acute bleeds on patients and their families.
Introduction
The World Health Organization in 1948 declared that health is a state of complete physical, mental, and social well-being and not merely the absence of disease. Quality of life (QOL) has been further defined as the patient's subjective perception of the impact of disease and its treatments on his or her daily life; physical, psychological, and social functioning; and well-being. In many chronic and/or progressive disorders, the concepts of QOL and burden of illness have been extended to include key caregivers affected by the often physical work of providing care, as well as psychosocial impact.
Congenital hemophilia A and B are rare X-linked bleeding disorders characterized by a deficiency in coagulation factor VIII (FVIII) or IX (FIX). Without consistent treatment such as routine FVIII or FIX replacement therapy to prevent bleeding, individuals with congenital hemophilia may experience recurrent bleeding, resulting in chronic arthritic pain and acute bleeding pain [1] . Treatment of frequent bleeding episodes and disability from hemophilic synovitis and arthropathy because of hemarthroses (joint bleeds) can result in decreased QOL for patients with congenital hemophilia and their caregivers. Even among patients with mild hemophilia A, joint damage because of prior hemarthroses has been shown to have a negative effect on physical health-related QOL [2] .
Because prevention and treatment of bleeding both are more challenging for patients with congenital hemophilia who develop alloantibodies ("inhibitors") to replacement FVIII or FIX, these patients have been observed to have more joint abnormalities and worse clinical/radiologic orthopedic scores than do age-matched hemophilia patients without inhibitors [3, 4] . For this reason, the gold standard in treatment has been to try to eliminate the inhibitor by immune tolerance induction, typically using FVIII, to restore the potential to reinstate routine FVIII replacement. Results of a recently discontinued international immune tolerance study, however, suggest that this might be effective only in approximately 54% of the young patients with good prognostic risk factors in the intent-to-treat population [5] .
For the estimated 800 to 1000 patients in the United States with congenital hemophilia complicated by inhibitors, acute bleeding episodes can be managed with infusions of bypassing agents such as recombinant activated factor VII (NovoSeven RT; Novo Nordisk A/S, Bagsvaerd, Denmark) and the older plasma-derived activated prothrombin complex concentrate (FEIBA NF; Baxter AG, Vienna, Austria) [6, 7] . In the developed world, patients with inhibitors most often treat themselves in the home setting [8] . Early treatment of bleeding episodes by using bypassing agents might minimize functional disability and preserve QOL for patients and caregivers [9, 10] . This suggests that the way patients and families manage the treatment of bleeding episodes at home, and how this affects daily life, deserves attention.
Quality-of-life assessments in patients with hemophilia complicated by inhibitors are affected not only by bleeding episodes but also by preexisting arthropathy and family circumstances (e.g., two or more children with hemophilia). As a result, periodic QOL assessments typically done on nonbleed days in prospective clinical studies may not accurately reflect the burden on patients and families. The Dosing Observational Study in Hemophilia (DOSE) was a prospective, observational diary study in which the primary objective was to evaluate the use of bypassing agents, with a focus on the use of recombinant activated factor VII in the home setting [11] . The secondary objective of the study was to evaluate the day-to-day variability in QOL for inhibitor patients (self-or caregiver-rated) and the impact of bleeding episodes on QOL for patients and their families. Furthermore, the study aimed to assess the correlation between QOL scores at monthly intervals and patients' average diary experiences to assess how reflective periodic assessments might be. This report focuses on results from QOL analyses from DOSE.
Materials and Methods

Study design
DOSE was a phase IV diary study conducted between January 2008 and July 2009 at 20 sites in the United States that were federally designated as hemophilia treatment centers (HTCs). Detailed methodology is described elsewhere [11, 12] . In brief, patients, or their caregivers, completed diaries for at least 90 days, or until patients experienced a minimum of four bleeding episodes. Bleed and treatment data were collected without the involvement of the HTC/physician to maintain the observational nature of the study and prevent changes in the treatment of the patient's disease due to additional patient/caregiver communication with the HTC/physician. Daily QOL analyses were a preplanned secondary objective of the study. The study was conducted with prior approval by local institutional review boards and with written consent from the subjects or their legal representatives.
Study population
Male patients with congenital hemophilia with inhibitors who experienced spontaneous bleeding were eligible for this observational study if they required treatment with bypassing agents for at least four bleeding episodes of any type in the prior 3 months and were prescribed recombinant activated factor VII as first-line therapy for bleeding episodes (including breakthrough bleeding with prophylaxis and immune tolerance therapy [ITT] ). Patients were categorized as on-demand treatment for bleeding (OD), secondary prophylaxis with bypassing agent (PPX), and/or ITT. Subjects received standard care according to local practice, and treatment decisions were made by the health care provider. Patients and caregivers were encouraged to communicate in a standard fashion with their treatment center during the study and to not share any diary materials or treatment logs that would not otherwise have been provided to their HTC.
Patient diaries
Patients or caregivers of minor patients kept daily diary records capturing information on bleed and treatment status and whether it was a work or school day for the patient or the caregiver. Daily QOL assessments by adult patients (or caregiver proxy assessments of QOL for their sons aged Յ 18 years) included the EuroQol five-dimensional questionnaire (EQ-5D), a generic measure of QOL that consists of five descriptive items (mobility, self-care, daily activities, pain/discomfort, and anxiety/depression), each with three levels of response (no, some problems, and extreme problems), and the standardized print presentation of a visual analogue scale (EQ-5D-VAS, 0 -100; higher scores indicate better health) [13, 14] . Permission of the EuroQOL Board [14] was obtained for the novel use of EQ-5D as part of a descriptive analysis on a daily basis as part of a diary, including caregiver assessment of QOL of their minor sons. In addition, adult patients (or caregivers assessing their minor sons) completed a standard 11-point Likert pain score (pain, 0 -10; higher scores indicating more pain) daily. To be able to assess the impact of bleeding on families of adult patients (spouses/partners, children) and children/adolescents (parents, caregivers, affected and unaffected siblings), novel rating scales for family anxiety/stress (none, slight, moderate, a lot, or extreme) and family activity changes (none, some, moderate, major) were developed on the basis of patient/caregiver consultations. Additional information was recorded on 24-hour bleed forms when a patient had a bleeding episode or reported ongoing treatment after bleeding had already ended. This information included details of the bleeding episodes (i.e., cause, type, location, and symptoms), all bleed treatments on an hour-by-hour basis, interference of bleeding episodes with daily activities (for patient and caregivers), reasons for treatment decisions, bypassing agent administered, pain medications, and pain levels at the time of each dose.
Patients/caregivers kept primary diaries on paper, with an optional Internet-based entry. Electronic diaries were submitted online in real time, whereas paper diaries were submitted monthly. The standardized 20-cm EQ-5D VAS [13] was used on the paper diaries and was transferred to electronic diaries as a numeric value either by patients/caregivers or entered into the electronic diary format by a third party (Outcome Sciences, Cambridge, MA). As Web-based entry of EQ-5D-VAS health scores as an integer on a 0 to 100 scale had not been validated, a preplanned analysis to correlate the reported VAS on the 20-cm scale with the number reported was performed and is reported with the study methodology [11] .
Patient and caregiver support
Throughout the study, an independent, dedicated patient-support liaison group (Outcome Sciences) provided logistical support to the patients and their caregivers. This individual contacted them for matters concerning training, data clarification, overdue forms, product box tops, and additional bleed forms and issued honoraria for study participation as approved by local institutional review boards. Electronic diary entry was monitored on a weekly basis, and paper-only diaries collected monthly.
Statistical analysis
U.S. preference-weighted EQ-5D index scores were calculated on the basis of the method developed by Shaw et al. [15] . All bleeds on all subjects were evaluated irrespective of treatment. Hierarchical models to control for repeated measures within patients, stratifi-cation, and comparison with mean nonbleed scores were used to evaluate instrument responsiveness to bleed and nonbleed days. QOL data were processed on all patients who had at least one bleeding episode and at least 7 days of QOL data past the end of the bleed. Additional post hoc analysis of this data included assessment of EQ-5D index, health, and pain scores across treatment groups and pediatric and adult age groups.
Results
Patient demographics and bleeding episodes
Of 52 patients enrolled in the study, 39 completed the daily diaries (23 adult diaries, 16 caregiver-reported diaries) and 37 completed daily QOL assessments (19 adult patients, 18 caregivers on behalf of patients). Baseline demographics and patient characteristics for enrolled and QOL populations are shown in Table 1 . Demographics of patients who completed the QOL assessments did not differ statistically from those of patients who did not complete the diary or QOL assessments in any measured characteristics. Approximately half of all enrolled and QOL patients were older than 18 years. The majority of enrolled/QOL patients were white (71.2%/ 73.0%) and non-Hispanic (65.4%/73.0%). Overall, about half had central venous access devices, and this was more commonly seen in children and adolescents. Slightly less than half had concomitant chronic illnesses, the most common of those being hepatitis C. Most patients were limited in recreational activities, work/ school, and/or self-care activities; only one quarter reported "unrestricted" functional status.
The median (range) number of historical bleeds over the prior 1 year was 13 (2-50), and the median duration of study participation was 91 days. Of the 39 patients who completed a diary, 38 reported 194 bleeding episodes and 1 had no bleeds during the diary completion period and was therefore not included in the bleeding and QOL analyses. The allocation of patients, number and frequency of bleeding episodes, and percentage of bleed days within the three treatment groups and within the adult/pediatric diaries are shown in Table 2 .
Quality-of-life assessments
Daily QOL assessments (including EQ-5D, EQ-5D-VAS, and pain score) were completed by 37 of the 39 patients who completed diaries, for a total of 3771 of 3777 diary days (99.8%). Of completed days, 472 (12.5%) were bleed days and 3299 were nonbleed days. Approximately half of the bleed days recorded in this study were not planned work or school days for patients (53%) or caregivers (48%). Apart from formal QOL assessments (described later), the specific impact of bleeding episodes on daily activities, productivity, and time spent with drug infusions is reported separately.
Across all diary days, the median (range) EQ-5D index, EQ-5D VAS, and VAS pain scores were 0.81 (Ϫ0.11 to 1.0), 83.0 (3.0 -100.0), and 1.0 (0.0 -10.0), respectively. Mean health scores were significantly worse on bleed days than on nonbleed days (P Ͻ 0.0001 for all) (Fig. 1 ). Mean health scores by patient were similar to aggregate scores across all patient diary days combined (Table 3) .
For all categorical component measures of QOL, the percentage of diary days with any problems was significantly higher (P Ͻ 0.0001) for bleed days versus nonbleed days: EQ-5D Fig. 2A) .
Similarly, across individual patient data, the percentage of patients with any problems with QOL in all categorical components was high on all diary days, bleed days, and nonbleed days (Fig. 2B ).
Patients had significantly higher percentages of reported problems in several EQ-5D dimensions (mobility [P ϭ 0.0242], usual activities [P ϭ 0.0060], and pain or discomfort [P ϭ 0.0462]) on bleed days (94.4, 94.4, and 94.4, respectively) than on nonbleed days (73.0, 67.6, and 75.7, respectively). In the other EQ-5D dimensions (self-care and anxiety or depression), EQ-5D VAS, and VAS pain, there was a trend toward lower QOL on bleed days than on nonbleed days, but the differences were not significant because a large proportion of patients reported a deviation from perfect QOL (or no pain) on both bleed and nonbleed days. The percentages of patients for whom the diary was taken in its entirety showed that "no problems" were low, even on nonbleed days: EQ-5D dimensionsmobility (27.0%), self-care (43.2%), usual activities (32.4%), pain or discomfort (24.3%), anxiety or depression (43.2%); EQ-5D index (13.5%); EQ-5D-VAS (2.7%); and VAS pain (27.0%) when analyzing on a per-patient basis.
Bleeding also affected family anxiety/stress and resulted in more changes to planned family activities (Fig. 3) . Across all diary days, bleed days had higher family anxiety and stress scores (42.4 vs. 29.7) and associated activity changes (34.5 vs. 21.2) than did nonbleed days. For patient-level data, there was a trend toward more abnormalities on bleed days than on nonbleed days. The percentage of patients with no abnormalities was low, even on nonbleed days, with 37.9% reporting at least some family anxiety/ stress and 43.2% reporting at least some activity changes.
Treatment regimens were not uniformly distributed by age, with adults constituting the majority of OD patients and pediatric patients constituting the majority of those on PPX and/or ITT. As a result, the PPX and ITT populations were generally younger and had differences noted in nonbleed day QOL (Table 3) . Across all diary days and mean scores by patient, scores were in most cases still significantly lower on bleed days across all treatment regimens. This discrepancy by age is further illustrated by a comparison of pediatric QOL data entered by caregivers with that of adults as shown in Table 4 . Across all diary days, bleed days were worse than nonbleed days (P Ͻ 0.0001) in both age groups across the three indices, and adults performed worse than children/adolescents (P Ͻ 0.0001) with greater disability, worse health, higher pain across all dairy days, bleed days, and nonbleed days. Hierarchical linear modeling of bleed and nonbleed days indicated that all QOL assessments (EQ-5D dimensions, EQ-5D index, EQ-5D VAS, VAS pain, family anxiety, and family activity change) were significantly associated with bleed versus nonbleed states (P Ͻ 0.001) after controlling for repeated measures within patients ( Table 5 ). The odds of reporting any problems on bleed days over nonbleed days were highest for EQ-5D dimensions, with unadjusted odds ratios of 5.97 (pain or discomfort), 3.85 (usual activities), 2.57 (self-care), 2.10 (anxiety or depression), and 1.90 (mobility). This was followed by family activity change (1.97), family anxiety and depression (1.74), and VAS pain (1.43). The QOL parameter most predictive of bleed state was the EQ-5D index, with an unadjusted odds ratio of 0.05. (Note that this index is inversely related to health, with 1.0 representing perfect health.)
The EQ-5D-VAS and pain scores for two representative patients are shown in Figure 4 , illustrating the high degree of variability in some patients. Patient 1 is a 14 year old with, at most, very early stage joint disease who functions with a nonbleed day VAS health score of 100 and a pain score of 0. With bleeds, health and pain scores are affected for about 1 to 3 days. Family anxiety and activ-
Fig. 2 -Report of any problems in QOL metrics. Identification of days with QOL affected: EQ-5D components (none vs. other), EQ-5D index (1 vs. <1), EQ-5D VAS (100 vs. <100), and pain score (0 vs. >0) in the QOL population across all diary days considered together (A) and within each patient (B). EQ-5D-VAS is abnormal in almost all patients at some time;
therefore, assessment for anything apart from "100" is not informative. The other measures are variably sensitive to bleeding days. Anxiety and depression seem the least sensitive and least prevalent. EQ-5D, EuroQol five-dimensional questionnaire; QOL, quality of life; VAS, visual analogue scale.
ity changes (not shown) were also relatively limited to these bleeding episodes. In contrast, patient 2 is a 41 year old with hemophilic arthropathy whose baseline heath scores are in the 60 to 80 range and whose pain scores are in the 5 to 7 range. Both scores show some periodicity to the fluctuations, and most bleeding episodes would be difficult to identify without being marked. Family anxiety/stress and activity changes were associated with many noted periodic increases in pain.
To better understand variability with bleed days, analysis was done on each QOL score or dimension on bleed days in reference to each patient's mean nonbleed day value for that score or component. For all patients and bleed types, 70.8% of bleed days had more than one QOL score that was greater than 1 SD from the patient's mean nonbleed scores. VAS pain had the highest percentage of bleed days, with scores greater than 1 SD from the mean (30.9%), whereas the anxiety and depression dimension of the EQ-5D was the least responsive (as might be expected) at only 9.2% (Fig. 5) . Across bleed types, results were comparable for joint and other bleed types; however, for muscle bleeds, scores for family anxiety and stress most frequently exceeded 1 SD from the mean. 
Discussion
The current analyses of DOSE were designed to understand the impact of bleeding episodes on the QOL of patients and caregivers in a home treatment setting and to obtain additional information about the burden of living with or caring for a child with hemophilia with inhibitors. The study was derived from a desire to quantify the feedback obtained from patients and caregivers serving on a series of advisory boards about the nature of living with hemophilia with inhibitors. Both groups were integral to devising the study and providing feedback on the planned data capture. The groups completed diaries on bleed and treatment status and performed daily QOL assessments, which showed that all QOL parameters were worse on bleed days and congruent with an increase in family anxiety and stress. These results were also in agreement with our expectations because the inhibitor population is distinctly different from the pediatric population of hemophilia patients without inhibitors, which, during the past 5 to 10 years, has grown up with the gold standard of routine factor replacement from birth (primary prophylaxis), providing an essentially normal, nearly bleed-free childhood for those with severe factor deficiencies. Secondary prophylaxis with bypassing agents serves to reduce the bleed frequency only by 45% to 60% [17] [18] [19] , as evidenced by our ability to recruit many secondary prophylaxis patients with frequent breakthrough bleeding. Thus, arthropathy is likely to occur in all inhibitor patients at some point in time even with prophylaxis.
Assessments of the impact of hemophilia with inhibitors on the QOL of patients and their families typically include periodic (likely nonbleed day) evaluations, reflecting baseline, day-today QOL impairment caused by the progression of hemophilia. Trials of bleeding treatments typically do not start in the middle of a bleeding episode, meaning that initial QOL samples are on a nonbleed day and, thus, better than the patient's average. Even frequent bleeders are not bleeding most of the time, and, in this study, only 8.9% of the overall days were associated with bleeding or bleed treatment. Patients typically do not come in for end-of-trial visits during a bleeding episode. Therefore, it is likely that periodic or end-of-study QOL assessments are also on nonbleed days. One implication of this is that periodic assessments, as currently executed in trials, do not necessarily capture more than the impact of any treatment intervention on the baseline QOL impairment and miss important QOL effects that occur during the brief treatment periods on bleed days. For those with arthropathy, baseline QOL is unlikely to be improved by a change in bleed-specific treatment and can only remain the same or get worse over the duration of a study.
To our knowledge, DOSE is the first diary study to look at daily QOL assessments in a chronic disease state, including EQ-5D. Daily assessments reveal additional information about the QOL effect of bleeding episodes in the acute setting and about QOL impairment associated with inhibitors in the long term. Younger patients, as shown in Figure 4A , may exist in a relatively normal health state between bleeding episodes. However, they and their families are significantly affected by bleeding and acute pain. Older patients with a history of ongoing bleeds into their joints, as shown in Figure 4B , have a vicious cycle of bleeding, acute synovitis with neovascularity, and rebleeding. The result of the cycle is adults who have chronic arthropathy with cartilage and bone changes and significant functional impairment. For those patients, discrimination between QOL effects attributable to bleed onset versus daily arthritic pain is reported as difficult. These daily data demonstrating the variability in particularly pain levels from day to day illustrate this patient dilemma.
DOSE is also the first study to proactively look at the impact of bleeding on patient and caregiver work/school by capturing planned work/school days instead of just "lost" days. Surprisingly, about half of the patient and caregiver bleed days were not planned work/school days. As diary completion was distributed throughout the year, this suggests that for adult patients with inhibitors, disability may be fairly common (i.e., no work/ school). In addition, for caregivers of these patients, at least one parent may electively not work or not work full time to better care for their child. In future studies, careful consideration must be given to documentation of patient disability, caregiver activities/work, and true lost work/school opportunities due to bleeding episodes versus to the underlying condition.
The results of DOSE do not suggest that daily QOL measurements could or should be the norm for assessing chronic diseases such as hemophilia. The results, however, illustrate the challenges in trying to quantify the burden of hemophilia and the impact on the patient and the family by using purely period assessments. Patients experienced no major difficulties completing QOL questionnaires on a daily basis. In fact, 37 of the 38 patients completing diaries and experiencing bleeding episodes were willing to participate in QOL assessments for a small additional honorarium. Different modes of data collection, paper as well electronic versions, were collected without a loss of patient reliability, and even EQ-5D-VAS measurements on paper correlated with the patient's reported numeric result on the Web-based entry system in real time, demonstrating the reliability of electronic data capture methods. Data collected on days 1, 30, 60, and 90 correlated to a moderate degree with the average patient experience over the interval.
Although the usefulness of daily QOL assessments in a prospective clinical study is unclear, a common challenge faced in hemophilia is to better characterize the effect of prophylaxis treatments (routine FVIII/FIX replacement or with bypassing agents for inhibitor patients) on QOL. The newer EQ-5D-5L scale was not validated at the time DOSE was initiated, but it might provide a similarly rapid but more discriminating assessment score [20, 21] . The newer EQ-5D-Y assessment scale for youths (age Ն 8 years) might have provided an alternative to caregiver assessment of their children/adolescents, but it was also still in development [22] . Hemophilia-specific tests may provide more sensitive analyses that can supplement the use of standard measures. There are only a few disease-specific QOL parameters, however, and most have been recently developed [23] [24] [25] [26] . The hemophilia-specific health-related QOL questionnaire was originally made available for use among children and adolescents [23, 25] , and a separate version has been developed independently for adults [26] . The hemophilia-specific health-related QOL questionnaire for adults "discriminates" between patients on the basis of severity of hemophilia and HIV status and has shown good correlation to results from the short form 36 health survey and the Health Assessment QuestionnaireFunctional Disability Index [26] .
Future clinical trials may help to provide a better understanding of the significance of using these tests; however, based on the data shown here, the baseline QOL assessments on the nonbleed start day of a short-term study (3-12 months) could easily reflect simply patient age and the presence of arthropathy (fixed joint damage) associated with prior joint bleeds. Even if the number of bleeds or the severity of bleeds was reduced, the data from DOSE suggest that it would be unlikely that a scheduled assessment at study completion would show improvement, and, given the possibility of bleeding on that day (see Fig. 4B ), might show worsening despite an obvious QOL improvement over the interval. In the short term of a typical study (3-12 months) , it is unlikely that baseline QOL on the nonbleed day of study start would improve by study completion because the study is not directed toward reducing inflamma- Fig. 5 -Proportion of bleed days that exceed 1 SD and 2 SD from patients' mean nonbleed scores. EQ-5D index, EQ-5D VAS, pain score, family anxiety/stress, and activity change scores. To the extent that each score is sensitive to the effect of acute bleeding, one might expect the proportions to exceed 1 or 2 SD from the patient's nonbleed day mean. EQ-5D, EuroQol five-dimensional questionnaire; VAS, visual analogue scale. tion, as might be the case in a trial of immune modulation for arthritis.
There are limitations of this study and these data. Although the sample size for DOSE was low (52 patients), which may limit statistical power, this sample constitutes nearly 7% of all US patients with high-titer inhibitors and had a 75% completion rate. It is well known that patients/caregivers sometimes complete bleed logs en route to a clinic visit. Electronic capture in real time for 24 of the 39 diaries with weekly monitoring, however, gives confidence that these reports were in real time, and in addition, review of the detailed monthly paper submissions reveals comments inserted in the margins, reflecting that the patients/caregivers likely completed (at least many paper diaries) in real time. Most of DOSE sites were large HTCs, might disproportionately treat patients with higher disease severity. Furthermore, patients in this study underwent a mix of treatment regimens, from OD through secondary PPX with bypassing agents to reduce bleed frequency. The mix of treatments is unequally distributed by age (adults were more likely OD), and the choice of treatment is likely affected by the severity or progression of arthropathy. Small numbers of particularly young children within the ITT and PPX groups coupled with potential overlap between those groups further limits analysis. Irrespective of treatment regimen, patients needed to meet an entry criterion of four or more bleeds in the previous 3 months, which, for patients taking prophylaxis and showing this many breakthrough bleeds, implies that their preprophylaxis bleed frequency may have been more than two to three bleeds per month. This also limits the generalizability of the QOL estimates in this study to patients who do not experience bleeds as frequently. In addition, while some QOL measures used were presented in their standard format (e.g., EQ-5D-3L with VAS), they have not been validated specifically for daily use or for use by caregivers in proxy rating of pediatric patients. In terms of proxy assessments by caregivers, the relatively nonoverlapping categories for mobility, self-care, and daily activities lend themselves more easily to proxy assessment than pain and anxiety/ depression, particularly when it comes to infants and small children who would be too young even for the new EQ-5D-Y tool [22] . The family anxiety/stress and activity change scales were unique to this study and were meant to be exploratory. There are also statistical considerations in multiple sampling of the same patient at frequent intervals.
Conclusions
Apart from the already reported, very interesting observations about home treatment and decision making by the patient/caregiver [11, 12] , DOSE demonstrated three key findings related to QOL. First, there are methodological limitations to the traditional periodic assessments, particularly given that baseline values are universally nonbleed days (best possible QOL). Second, patients with chronic arthropathy have more impairment in baseline QOL and have variability in nonbleed days that would likely be common with any degenerative joint disease or chronic disease characterized by an episodic course. Last, as expected, bleeding days are worse and are particularly marked by reduced patient and family activity with more pain. Thankfully, bleeding days represent a minority of the patient's life, and there are other factors that more significantly affect overall score and day-to-day variability in the nonbleeding state. New approaches are required to adapt validated health-related QOL assessment tools for more frequent assessments that can help quantify the cumulative impact of acute bleeding associated with different treatment paradigms on the patient, as well as assess the QOL impact and burden on the caregiver and family.
